Update October 27, 2021 at end
Palmer Foundations reports by way of Trial Site News Combination Therapy For COVID-19 Based on Ivermectin in an Australian Population. Excerpts in italics with my bolds.
The immediacy of “real-world” data in the pre-hospital treatment of Covid-19 using re-purposed drugs has been the keystone to the development of effective therapy in a pandemic situation. The sense of a “common-message database” for the therapeutic use of ivermectin (IVM) collated by clinicians over a time frame of little more than 12 months, involving patients and research workers across geographic and social lines, is extraordinary.
From over 20 countries there are 63 controlled studies accepted for meta-analysis, that have included 47,500 subjects with 625 authors.
While this compelling database on the effectiveness of IVM would not be possible without “real-life” studies, at an individual level, these trials give additional value such as information on dosage and combination therapies. They also give confidence to local doctors and regulators as they seek optimal management strategies.
Here, we report successful pre-hospital treatment of Covid-19 patients in Sydney and Melbourne, Australia, using an ivermectin-doxycycline-zinc combination with an important set of observations on symptom resolution and oximetry.
Six hundred Australian residents with positive PCR symptomatic Covid-19 were treated with a combination of ivermectin (24 mg per day), doxycycline (100 mg bd), and zinc (50mg per day), for 10 days within 48 hrs of obtaining a positive PCR test for Covid-19. The treatment period was from June to September 2021. Seven percent (7%) were given additional vitamins and nutritional supplements. Only 7% identified adverse events from the therapy, mainly minor gut symptoms of nausea, diarrhoea and heartburn. No patient stopped therapy due to adverse drug events.
A subgroup in hotel and home quarantine was available for a more detailed assessment of symptoms and oxygenation status. This cohort of 126 was assessed for 10 symptoms according to a visual analogue scale (ranging from “0” for no symptoms, to “10” for most severe symptoms). Descriptive statistics are summarised in Table 1. P-Values were calculated using Wilcoxon matched-pairs signed-rank t-tests. Chi Squared analysis was used to analyse rates of hospitalization in the 600-patient cohort.
A total of 600 patients with positive PCR tests were treated with the ten-day course of “Ivermectin Triple Therapy” (ITT), which was fully completed in over 90% of those treated. None discontinued therapy as a result of drug side effects. Two visited the hospital for less than 24 hours following a transient arrhythmia and then went home, while five were admitted to hospital (0.83%). There were no deaths.
In an equivalent control group of 600, not treated with triple therapy, 70 were admitted to hospital (11.5%), with 6 deaths (1%). Chi-squared analysis of hospitalisation rate shows a significant decrease (P<0.001) in the presence of ivermectin triple therapy intervention. The control data was from contemporary infected subjects in Australia obtained from published Covid Tracking Data.
The subgroup of 126 in quarantine had more detailed documentation. They had an average age of 42 (range: 17-94). The results of symptom analysis are in Table 1. For the 10 symptoms analysed, 98% had a total symptom score severity reduction by the end of the treatment period (P< 0.0001). Symptoms that were most persistent were loss of taste and smell, cough, and fatigue. Oximetry readings in 71 subjects were consistent with mild disease in most (Table 1), though the range extended to the low 70’s indicating severe disease in some individuals. At the completion of the 10 -day treatment programme, all subjects had normal oximetry readings.
This successful study of 600 consecutive subjects treated within 2 days of testing positive on PCR for Covid-19 infection, emphasises the value of early treatment. The results are consistent with the study by Hazan et al, further supporting the value of ITT therapy (ivermectin, doxycycline and zinc).1 The current study differs from that of Hazan et al who successfully used lower doses of IVM and a shorter treatment duration. The current study also confirms the value of oximetry in monitoring response to therapy, with all hypoxic patients having normal oximetry levels following the treatment protocol. Few become hypoxic in the first 48 hours of symptoms. The rapid increase in oximetry values following IVM, noted by Hazan1, confirms significant hypoxia was likely avoided in this treated group. Combining oximetry with visual analogue scales to monitor symptoms, is suggested as a valuable tool for future studies.
Visual analogue scale monitoring of symptoms of Covid-19 infection showed a fall from a median total symptom severity score of 37 (range: 0-100) at the onset of treatment to 3 (range: 0-62) at the conclusion of treatment (P<0.0001). The main persistent symptoms were loss of smell/taste, cough and fatigue, recognised to persist for longer periods, however, all displayed significant severity score reductions during the treatment period (P<0.0001). The impact of early treatment with ITT on subsequent “long Covid” will be an important question to pursue. Symptom resolution with untreated Covid-19 is generally 2-4 weeks, emphasising the value of visual analogue scale assessment.
The major differences in admission to hospital and death following ITT therapy compared to contemporary controls is consistent with the large and increasing body of data measuring the impact of ivermectin-combination therapy.1–3 The results from this study invites comparison with recently announced data by Merck from a study of their re-cycled antiviral polymerase inhibitor, Molnupiravir. The Merck study with 385 treated patients involved a similar group to that treated in the current Australian study judged by near-identical hospital admission and mortality rates in both control groups. In the Merck study, the hospital admission rate was halved (7.3% of treated patients) with no deaths, similar to data for the “first cousin” of Molnupiravir, Favipiravir, which is used extensively in Russia. The important point is that the admission rate in the Merck study is 8-fold greater than the 90% reduction in hospital admissions recorded in the current ITT study (P<0.0001).
The public health impact of these findings with a cheap, safe and available therapy, in terms of reduction of load on a health system that will be further stressed as country borders are re-opened, cannot be ignored.
The current study included “real-life” data on consecutive patients thus avoiding selection bias. Therapy was given in two states of Australia, involving over 30 front-line doctors. This compelling data reinforces the value of information from a range of sources and trial methodologies in assessing treatment options, especially in a pandemic situation. The number of patients in this report was capped at 600, as the Australian regulatory body (the TGA) intervened in the middle of Australia’s third Covid wave, to prohibit further prescription of ivermectin for Covid-19 by General Practitioners.
Update October 27, 2021
From medRxiv paper Effectiveness of Ivermectin-Based Multidrug Therapy in Severe Hypoxic Ambulatory COVID-19 Patients:
Regarding strategies in the development of combination therapies, intracellular coronavirus replication requires several active drugs to inhibit viral replication. IVM, doxycycline and zinc all individually inhibit coronavirus replication and, although there are other candidates, we have proposed the above combination based on efficacy, component safety profiles, inexpensive nature, and lack of drug-drug interaction. The combination of IVM and doxycycline has also been demonstrated to act in synergy against COVID-19 . This combination also appears to overcome the need for high doses of IVM identified by Caly and colleagues when used alone. Further, given that zinc plays a key role in antiviral activity  it would combine well with the ionophores (IVM and doxycycline) to increase its intracellular concentration and expedite viral clearance .
We have also assessed drug-drug interactions and found that the combination of zinc with IVM and doxycycline has no reported interactions. Additionally, each of these drugs has a low adverse side effects profile and no QT prolongation as reported with azithromycin.
Overall, based on the current literature, a 10-day combination therapy of IVM, doxycycline and zinc will not only improve symptoms [6,7] but also accelerate recovery from COVID-19. We have chosen a safe IVM dosage approved for parasites of 36mg over 10 days, and this dose has been shown to be both effective and safe in COVID-19 treatments . The staggered IVM dosage over 10 days is proposed based on the half-life clearance of the drug in plasma (up to 66 hrs.). The proposed duration would allow constant availability of adequate plasma level IVM to facilitate zinc entry into the cells. Hence, the above rationale explains why some publications have already shown that IVM alone is not adequate to cure COVID-19 [6,18,19] while a multidrug regimen is likely to be more efficacious .
“They had an average age of 42” This is very young. I’d want to see the ages of the participants and the controls.
That refers to the 126 in quarantine, age range 17 to 94. I haven’t seen a more detailed paper/
We still don’t know the ages of the rest.
Click to access 2021.07.06.21259924v1.full.pdf
That’s a different study than the one in your post.
I know. The 600 patient study doesn’t provide more detail than this:
Click to access TrialSite-media-release-19.10.2021.pdf
More on Dr. Borody here:
This reinforces the evidence of successes elsewhere. Cheap & effective remedies are not appealing to Big Pharma, and remain banned by those with vested interests. Someone needs to force-feed this to the Victorian Premier, Dan Andrews & others.
Ron, FYI: Norton 360 red-flagged this post, my email notification of this post, and all of rclutz dot com. I had them research it, and today it’s back to normal. You can delete this comment after you see it.
Thanks Hifast. Good to know you are watching the watchers.
Reblogged this on muunyayo .
we’ve had anecdotal evidence that the Ivermectin triad is highly effective since last year as various doctors around the world tried it in their wards and then published the results.
Proof in the pudding: Uttar Pradesh state in India and Indonesia both did massive Ivermectin kit intervention when their countries got hit with a massive spike in infections. In a matter of weeks, infections and deaths plummeted and remain low to zero.
Yet we hear little on other treatments beyond the vaccine here in Aus and overseas studies are given little credibility.
You could almost say that there could be money involved.